Precision medicine company Tempus AI Inc (NASDAQ: TEM) announced on Wednesday that it has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its AI-based Tempus ECG-AF device, which identifies patients at increased risk of atrial fibrillation/flutter (AF). This clearance is the first for AF in the 'cardiovascular machine learning-based notification software' category, enabling physicians to incorporate this algorithm into patient care.
AF, a leading cause of stroke, affects millions and is challenging to diagnose. Tempus' AI-driven clinical solutions aim to facilitate early identification of cardiovascular diseases. ECG-AF, the first in a suite of diagnostics, analyzes 12-lead ECG recordings to detect AF signs within the next 12 months in patients aged 65 and older without a known history of AF.
The device is designed to be used alongside other diagnostic information, including original ECG recordings, tests, and the patient's clinical history. It is not meant to provide a comprehensive risk assessment or serve as the sole basis for AF diagnosis or treatment.
Tempus leverages AI and one of the world's largest libraries of multimodal data to deliver personalised patient care and advance therapeutic discovery and development.
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Genetesis' CardioFlux Magnetocardiograph receives Health Canada approval
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
Bayer launches Phase II study for chronic kidney disease treatment
Johnson & Johnson agrees acquisition of V-Wave
AbCellera expands collaboration with Lilly
AstraZeneca's Calquence combo improves 1L CLL progression-free survival
Destiny Pharma's XF-73 nasal gel reduces antibiotic use in cardiac surgery patients